Title:
THERAPEUTIC AGENT FOR HIGH-RISK MYELOFIBROSIS
Document Type and Number:
WIPO Patent Application WO/2023/175932
Kind Code:
A1
Abstract:
The present invention relates to a novel therapeutic agent for high-risk myelofibrosis, said agent containing a compound represented by general formula [1] (in the formula, R1, R2, R3, R4, R5, and X are as defined in the description) or a pharmaceutically acceptable salt thereof as an active ingredient.
Inventors:
UNO TOMONORI (JP)
Application Number:
PCT/JP2022/012705
Publication Date:
September 21, 2023
Filing Date:
March 18, 2022
Export Citation:
Assignee:
NIPPON SHINYAKU CO LTD (JP)
International Classes:
A61K31/497; A61P7/00
Domestic Patent References:
| WO2010090290A1 | 2010-08-12 |
Other References:
VERSTOVSEK S, TALPAZ M, RITCHIE E, WADLEIGH M, ODENIKE O, JAMIESON C, STEIN B, UNO T, MESA R A: "A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis", LEUKEMIA, NATURE PUBLISHING GROUP UK, LONDON, vol. 31, no. 2, 1 February 2017 (2017-02-01), London, pages 393 - 402, XP093092316, ISSN: 0887-6924, DOI: 10.1038/leu.2016.215
ANONYMOUS: "NS-018", MEDKOO BIOSCIENCES, 1 January 2017 (2017-01-01), pages 1 - 2, XP093092776, Retrieved from the Internet [retrieved on 20231018]
ANONYMOUS: "NS-018", MEDKOO BIOSCIENCES, 1 January 2017 (2017-01-01), pages 1 - 2, XP093092776, Retrieved from the Internet
Attorney, Agent or Firm:
HASEGAWA Yoshiki et al. (JP)
Download PDF: